An analysis of biological input registration applications submitted to Brazil's Ministry of Agriculture, Livestock and Food Supply (MAPA) in 2025 reveals a market in transition. While traditional microorganisms still dominate in terms of registration volume, the market is simultaneously experiencing robust innovative momentum, marking an intertwined period of transformation. Three classic fungi stand out prominently, collectively accounting for over 50% of registrations: Beauveria bassiana leads with a 24.7% share, followed by Trichoderma harzianum (18.3%) and Metarhizium anisopliae (11.8%). These microorganisms form the core of Brazil's biological pest and disease control system.

The dominant position of these traditional microorganisms stems from the dual advantages of "proven efficacy and regulatory convenience". As high-efficiency insecticides, Beauveria bassiana and Metarhizium anisopliae demonstrate remarkable effectiveness in controlling pests such as whiteflies, leafhoppers, and coffee berry borers. Trichoderma harzianum, meanwhile, serves as a multi-functional agent, combining the properties of a microbial fungicide and a plant growth promoter, which optimizes root colonization environments and regulates soil microbial balance, enabling its wide application across diverse agricultural scenarios.

More importantly, years of field practice have fully validated the efficacy stability of these classic strains. Regulatory authorities possess in-depth knowledge of their biological characteristics and safety profiles, allowing their registration and approval processes to bypass the cumbersome evaluations required for new microorganisms. This significantly higher market entry efficiency has solidified their sustained competitive advantage.

Despite the continued dominance of traditional fungi, the trend of market transformation has become increasingly evident. GoGenetic, a key industry player, has identified a critical shift: in recent months, there has been a substantial surge in corporate demand for genetic identification services for exclusive microbial strains and exclusive rights to solutions. A consensus has emerged in the R&D sector that product differentiation must be achieved through the development of new technologies, novel microorganisms, and exclusive strains, breaking free from reliance on generic formulations.

This trend reflects a profound upgrade in corporate strategic awareness. As the biological inputs market matures, competition has shifted from homogeneous generic formulations to exclusive genetic resources. Exclusive strains, with their characteristics of precise control and environmental adaptability, offer far greater market value than ordinary products and have become the cornerstone for enterprises to build core competitiveness. This cognitive shift has directly driven adjustments in investment priorities. A growing number of enterprises are increasing investments in strain isolation, genetic identification, and intellectual property protection,establishing a full-chain R&D system encompassing "exploration-identification-protection"—exploring unique strains through ecological prospecting, analyzing functional characteristics via gene sequencing technology, and constructing barriers through patent. This system lays a solid foundation for differentiated competition.

Notably, amid the transition toward innovation, enterprises continue to adopt a pragmatic "broad-spectrum" strategy to secure their current market position. Registration data indicates that product applications focus on catastrophic pests and diseases such as whiteflies, Sclerotinia sclerotiorum, silverleaf whiteflies, and southern blight. Regulatory descriptions frequently employ the phrase "suitable for all crops infested by target organisms," highlighting a clear inclination toward developing broad-spectrum products.

This strategy achieves a win-win outcome of "maximizing market coverage while minimizing regulatory costs." On one hand, a single broad-spectrum product can be adapted to multiple major crop scenarios such as soybeans and sugarcane, significantly expanding market reach. On the other hand, there is no need to complete separate registration processes for different crops, which not only avoids the risk of delayed market access but also substantially reduces compliance costs. This accelerates the commercialization process and provides stable financial support for corporate R&D investments.

Advancements in technology and the maturation of biotechnology are driving Brazil's biological inputs industry into a new innovation cycle centered on personalization. Tadra, CEO of GoGenetic, notes that genetics and personalization will become the core of the industry's future development. Enterprises' pursuit of in-depth microbial understanding and exclusive rights to strains is an indispensable path toward developing more efficient, stable, and sustainable products.

This judgment points to a clear industry trajectory: the future will witness an upgrade from single microbial formulations to microbial composites, significantly increasing product functional complexity. Composite products can integrate multiple functions such as insecticidal, fungicidal, and growth-promoting capabilities, better meeting the comprehensive needs of modern agriculture. However, this upgrade is highly dependent on advanced genetic identification technology—only through precise analysis of strain genetic characteristics can the compatibility, stability, and functional complementarity between different strains be ensured.

This technical threshold will reshape the market competition landscape: enterprises equipped with high-end R&D facilities and core identification technologies will seize opportunities through their technical advantages, while those still relying on traditional strains and lacking innovation capabilities will gradually lose competitiveness. Tadra further predicts that innovative trends currently confined to the R&D phase will become industry norms in the short term. The registration volume of new microorganisms and biological composites will surge significantly, and product functions will evolve from single pest and disease control to the more ecologically valuable reconstruction of soil microbial balance.

Driven by both market transition and technological upgrading, the competitive landscape of Brazil's biological inputs market is undergoing a profound reshaping. As a major global agricultural power, Brazil boasts a promising biological inputs market, projected to exceed $3 billion in scale over the next decade. This immense market potential has attracted a dense influx of domestic and foreign enterprises, intensifying market competition.

The transition toward exclusive strains with clear genetic characteristics has become a key differentiator of corporate competitiveness—the logic of market competition has shifted completely from "price-oriented" to "performance-oriented". Enterprises with strong R&D capabilities can achieve core advantages such as improved control efficacy and enhanced environmental compatibility through the development of exclusive strains. Their high-efficiency, low-residue biological pesticides are more aligned with the global demand for sustainable agricultural development, enabling them to quickly establish differentiated competitiveness in the market and gradually capture core market share.

Meanwhile, intellectual property has become the core of competitive barriers. Through patent filings for new strains or composite combinations, enterprises can effectively prevent imitation and infringement, safeguarding returns on innovation investments. This virtuous cycle of "R&D + patents" will drive innovative enterprises to continuously increase investments, further widening the competitive gap with their peers.

More notably, with the gradual improvement of Brazil's biological inputs regulations, industry access standards are continuously rising, and first-mover advantages have become increasingly prominent. Enterprises that take the lead in deploying genetic identification and exclusive strain R&D can quickly establish dual technical and commercial barriers: developing high-efficiency products better aligned with market demand through technical reserves, consolidating market channels through industrial chain integration capabilities, and responding rapidly with mature compliance systems after the implementation of new regulations. This will drive the market pattern to concentrate around innovation leaders, while enterprises with lagging technology and delayed deployment may be gradually marginalized.

For all market participants, the current period represents a critical strategic window. Enterprises must not only rely on traditional broad-spectrum products to consolidate existing market share and support innovation investments but also seize the core trend of genetic identification and exclusive strain R&D by increasing technical and financial investments to build differentiated competitiveness.

In summary, Brazil's biological inputs market is undergoing a profound transition from "traditional reliance" to "innovation-driven development". The solid foundation of classic microorganisms and the innovative momentum of exclusive strains intersect, delineating a clear trajectory of industry transformation. This transformation is not only crucial to the sustainable development of Brazil's domestic agriculture but also serves as an important model for the global agricultural biological inputs industry, offering valuable experiences for market development in various countries.

In the future, only enterprises that take technological innovation as their core driving force, accurately grasp market transformation trends, and achieve synergy between short-term gains and long-term layout will stand firm in the increasingly fierce competition and inject sustained impetus into the global green agricultural development.